SI3149031T1 - T-celični receptorji proti humanemu papilomavirusu 16 E7 - Google Patents

T-celični receptorji proti humanemu papilomavirusu 16 E7

Info

Publication number
SI3149031T1
SI3149031T1 SI201531126T SI201531126T SI3149031T1 SI 3149031 T1 SI3149031 T1 SI 3149031T1 SI 201531126 T SI201531126 T SI 201531126T SI 201531126 T SI201531126 T SI 201531126T SI 3149031 T1 SI3149031 T1 SI 3149031T1
Authority
SI
Slovenia
Prior art keywords
cell receptors
human papillomavirus
papillomavirus
human
receptors
Prior art date
Application number
SI201531126T
Other languages
English (en)
Slovenian (sl)
Inventor
Christian S. Hinrichs
Steven A. Rosenberg
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of SI3149031T1 publication Critical patent/SI3149031T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
SI201531126T 2014-05-29 2015-05-29 T-celični receptorji proti humanemu papilomavirusu 16 E7 SI3149031T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004335P 2014-05-29 2014-05-29
EP15729004.0A EP3149031B1 (en) 2014-05-29 2015-05-29 Anti-human papillomavirus 16 e7 t cell receptors
PCT/US2015/033129 WO2015184228A1 (en) 2014-05-29 2015-05-29 Anti-human papillomavirus 16 e7 t cell receptors

Publications (1)

Publication Number Publication Date
SI3149031T1 true SI3149031T1 (sl) 2020-07-31

Family

ID=53396593

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531126T SI3149031T1 (sl) 2014-05-29 2015-05-29 T-celični receptorji proti humanemu papilomavirusu 16 E7

Country Status (20)

Country Link
US (4) US10174098B2 (enExample)
EP (3) EP3689900B1 (enExample)
JP (5) JP6742991B2 (enExample)
KR (2) KR102445667B1 (enExample)
CN (2) CN113150112B (enExample)
AU (5) AU2015266818B2 (enExample)
CA (1) CA2950192A1 (enExample)
CY (1) CY1122790T1 (enExample)
DK (1) DK3149031T3 (enExample)
ES (1) ES2784237T3 (enExample)
HR (1) HRP20200376T1 (enExample)
IL (3) IL290655B2 (enExample)
LT (1) LT3149031T (enExample)
MX (2) MX375379B (enExample)
PL (1) PL3149031T3 (enExample)
PT (1) PT3149031T (enExample)
SA (1) SA516380394B1 (enExample)
SI (1) SI3149031T1 (enExample)
SM (1) SMT202000143T1 (enExample)
WO (1) WO2015184228A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3149031T3 (da) 2014-05-29 2020-03-16 Us Health Anti-human papillomavirus 16 e7 t-cellereceptorer
WO2016179006A1 (en) * 2015-05-01 2016-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
CN108884140B (zh) 2015-12-03 2022-10-25 朱诺治疗学股份有限公司 修饰的嵌合受体及相关组合物和方法
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
RU2019112860A (ru) 2016-09-27 2020-10-30 Серо Терапьютикс, Инк. Молекулы химерных интернализационных рецепторов
EP3519433A1 (en) * 2016-10-03 2019-08-07 Juno Therapeutics, Inc. Hpv-specific binding molecules
JP7685735B2 (ja) * 2016-12-02 2025-05-30 アンヘレス セラピューティクス インコーポレイテッド 合成免疫受容体およびその使用方法
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CA3062433A1 (en) * 2017-05-15 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
CN110914295B (zh) * 2017-06-28 2024-08-09 里珍纳龙药品有限公司 抗人乳头瘤病毒(hpv)抗原结合蛋白及其使用方法
AU2018341244A1 (en) 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
MA50651A (fr) 2017-09-29 2020-08-05 Us Health Récepteurs de lymphocytes t reconnaissant p53 mutée
EP3692063A1 (en) * 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
CA3077595A1 (en) * 2017-10-05 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing, monitoring and treating neurological diseases and disorders
EP3707258A1 (en) 2017-11-06 2020-09-16 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
CN118374524A (zh) 2018-02-09 2024-07-23 美国卫生和人力服务部 拴系白细胞介素-15和白细胞介素-21
MX2020010235A (es) * 2018-03-28 2020-10-28 Cero Therapeutics Inc Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
EP3774865A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
EP3775238A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
AU2019247199A1 (en) 2018-04-05 2020-10-15 Editas Medicine, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
CN112262212B (zh) 2018-04-24 2024-07-12 美国卫生和人力服务部 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
WO2019243888A1 (en) * 2018-06-22 2019-12-26 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
MX2021002574A (es) 2018-09-11 2021-06-08 Juno Therapeutics Inc Metodos para el analisis por espectrometria de masas de composiciones de celulas modificadas.
JP7713886B2 (ja) 2018-11-30 2025-07-28 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
EP3986450A4 (en) * 2019-06-20 2023-06-28 Memorial Sloan Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
WO2020264269A1 (en) 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
CN110357952B (zh) * 2019-07-17 2022-03-22 深圳市因诺转化医学研究院 识别人乳头瘤病毒hpv16-e7抗原的tcr
KR20220119439A (ko) 2019-12-20 2022-08-29 인스틸 바이오 유케이 리미티드 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도
JP7614659B2 (ja) * 2019-12-30 2025-01-16 ブリスター イムノテック リミテッド 強化されたｔ細胞受容体ｓｔａｒ及びその用途
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN113072635B (zh) * 2020-01-06 2023-08-25 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的t细胞受体及其编码序列
CA3187163A1 (en) * 2020-05-07 2021-11-11 China Immunotech (Beijing) Biotechnology Co., Ltd Improved t cell receptor-costimulatory molecule chimera
JP7591772B2 (ja) * 2020-05-25 2024-11-29 ブリスター イムノテック リミテッド 強化された合成ｔ細胞受容体及び抗原受容体
CN116096740A (zh) * 2020-06-09 2023-05-09 得克萨斯州大学系统董事会 经改造t细胞受体和使用方法
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
CN116472050A (zh) 2020-09-04 2023-07-21 美国卫生和人力服务部 识别p53中r273c或y220c突变的t细胞受体
WO2022060904A1 (en) * 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
WO2022104035A2 (en) 2020-11-13 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
CN117957245A (zh) 2021-05-07 2024-04-30 美国政府(由卫生和人类服务部的部长所代表) 识别p53中的c135y、r175h或m237i突变的t细胞受体
CN117897411A (zh) * 2021-06-30 2024-04-16 华夏英泰（北京）生物技术有限公司 一种多靶点合成t细胞受体抗原/抗体受体及其应用
EP4384543A4 (en) * 2021-09-07 2025-06-11 Corregene Biotechnology Co., Ltd. ANTIGEN-BINDING PROTEINS AND USES THEREOF
JP2024538169A (ja) * 2021-10-18 2024-10-18 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｎｄｃ８０抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
CA3237646A1 (en) * 2021-11-10 2023-05-19 Tscan Therapeutics, Inc. Binding proteins recognizing hpv16 e7 antigen and uses thereof
US20250134999A1 (en) 2022-01-14 2025-05-01 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
CA3247927A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
US20250243260A1 (en) 2022-03-07 2025-07-31 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
CN115286698B (zh) * 2022-05-10 2023-09-01 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
CN116731155B (zh) * 2022-09-21 2024-03-22 新景智源生物科技(苏州)有限公司 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途
KR20250174626A (ko) 2023-03-27 2025-12-12 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 P53의 y220c 또는 r175h 돌연변이를 표적화하는 t 세포 수용체
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025096419A1 (en) * 2023-10-31 2025-05-08 Lyell Immunopharma, Inc. T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025193926A1 (en) 2024-03-15 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting e545k or n345k mutation in pik3ca
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
WO2006103429A2 (en) * 2005-04-01 2006-10-05 Medigene Limited High affinity hiv t cell receptors
AU2007248019B2 (en) * 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
JP6035503B2 (ja) 2007-05-31 2016-11-30 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するｔ細胞によって標的とされるｈｐｖエピトープ
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
GB0917090D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
DK3149031T3 (da) * 2014-05-29 2020-03-16 Us Health Anti-human papillomavirus 16 e7 t-cellereceptorer

Also Published As

Publication number Publication date
HRP20200376T1 (hr) 2020-08-07
US20210130432A1 (en) 2021-05-06
EP4609876A3 (en) 2026-01-21
AU2015266818A1 (en) 2016-11-24
JP7535158B2 (ja) 2024-08-15
IL290655A (en) 2022-04-01
AU2019283892A1 (en) 2020-01-23
JP7291196B2 (ja) 2023-06-14
SA516380394B1 (ar) 2021-01-05
JP7744479B2 (ja) 2025-09-25
JP2024156861A (ja) 2024-11-06
IL290655B1 (en) 2024-01-01
IL290655B2 (en) 2024-05-01
CN106661098B (zh) 2021-05-04
PL3149031T3 (pl) 2020-08-24
KR20220130267A (ko) 2022-09-26
PT3149031T (pt) 2020-03-25
US20220372103A1 (en) 2022-11-24
JP6997267B2 (ja) 2022-02-04
JP2023110036A (ja) 2023-08-08
US20190085047A1 (en) 2019-03-21
JP2017524372A (ja) 2017-08-31
CN113150112A (zh) 2021-07-23
US20170145070A1 (en) 2017-05-25
WO2015184228A1 (en) 2015-12-03
IL282518A (en) 2021-06-30
EP3689900B1 (en) 2025-07-23
MX2020010035A (es) 2020-10-14
JP2021000089A (ja) 2021-01-07
KR20170003939A (ko) 2017-01-10
CA2950192A1 (en) 2015-12-03
AU2021202227A1 (en) 2021-05-06
KR102618267B1 (ko) 2023-12-27
AU2021202227B2 (en) 2022-11-10
KR102445667B1 (ko) 2022-09-21
AU2015266818B2 (en) 2019-10-03
AU2023200608B2 (en) 2024-08-22
SMT202000143T1 (it) 2020-05-08
US10870687B2 (en) 2020-12-22
US11434272B2 (en) 2022-09-06
EP3149031A1 (en) 2017-04-05
DK3149031T3 (da) 2020-03-16
LT3149031T (lt) 2020-05-25
AU2019283892B2 (en) 2021-01-28
CN113150112B (zh) 2024-02-06
CN106661098A (zh) 2017-05-10
EP4609876A2 (en) 2025-09-03
AU2023200608A1 (en) 2023-03-09
ES2784237T3 (es) 2020-09-23
IL248797B (en) 2021-05-31
MX375379B (es) 2025-03-06
US10174098B2 (en) 2019-01-08
EP3149031B1 (en) 2019-12-18
US12534508B2 (en) 2026-01-27
MX2016015383A (es) 2017-02-28
EP3689900A1 (en) 2020-08-05
IL282518B (en) 2022-04-01
BR112016027805A2 (pt) 2017-10-24
JP6742991B2 (ja) 2020-08-19
IL248797A0 (en) 2017-01-31
AU2024266702A1 (en) 2024-12-12
CY1122790T1 (el) 2021-05-05
JP2022058360A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
IL248797A0 (en) 16 e7 against the human papillomavirus t cellular celts
IL285287B1 (en) Antibodies to tigit
ZA201701823B (en) T cell receptors
SG10201913978RA (en) Anti-mutated kras t cell receptors
IL250536A0 (en) Chimeric antigen receptors
IL251030A0 (en) Chimeric antigen receptors
IL246661B (en) Human antibodies to pd–l1
EP3098888A4 (en) Redox flow battery
SG11201510157YA (en) T cell receptors
GB2543462B (en) Multi-functional charger
EP3240084A4 (en) Redox flow battery
EP3145016A4 (en) Redox flow battery
PT3178929T (pt) Novo anticorpo anti-ig(beta) humana
EP3109933A4 (en) Redox flow battery
HK1238270A1 (en) T cell receptors
GB201411761D0 (en) Soluble-lead redox flow battery
ZA201508345B (en) Back up fall arrestor
AU356621S (en) Utility can